<DOC>
	<DOC>NCT01151085</DOC>
	<brief_summary>To collect the efficacy and safety informations of voriconazole related to their appropriate use in daily practice.</brief_summary>
	<brief_title>Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the subjects whom an investigator prescribes the first voriconazole (VFEND) should be registered consecutively until the number of subjects reaches target number in order to extract subjects enrolled into the investigation at random.</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Male or Female subjects intend to treat their deep mycosis who are prescribed voriconazole (VFEND) by their Physicians. Subject who heve been prescribed voriconazole (VFEND) before.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Systemic Mycosis</keyword>
	<keyword>Aspergillus infection</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Cryptococcal infections</keyword>
	<keyword>Japanese</keyword>
	<keyword>voriconazole</keyword>
	<keyword>VFEND</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan.</keyword>
</DOC>